| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-11-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-12-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-28-2025 | 12-31-2024 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ: MDCX) with a Buy and maintains $27 price target.
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of t...
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively tr...
-SEC Filing
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on adva...
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
